FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Buy Rating On Shares Of Cvs Health Corporation

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month price target to $110 from $100, 14.8x our 2026 EPS estimate, above CVS's three-year and five-year average forward multiples of 9.8x and 10.3x, respectively. We raise our 2026 EPS estimate by $0.03 to $7.43 and our 2027 estimate by $0.10 to $8.36. Shares recently yielded 2.8%. While execution risks remain, we think CVS is executing well under its turnaround strategy, supporting our expectations for consistent earnings per share and free cash flow growth through the end of the decade. Though the health insurance operation (Aetna) remains pressured by an environment of elevated medical cost trends, we think Pharmacy & Consumer Wellness appears to be on more stable footing, with the company recently updating long-term segment earnings projections to at least flat vs. the prior view of 5% annual declines. After shedding hundreds of stores as part of its restructuring, the business is expanding to new locations, including smaller, pharmacy-only stores with less general merchandise.

Related Articles

Research

Maybank Securities Upgrades Thai Beverage Public Company to Buy from Hold, Adjusts Price Target to SG$0.48 from SG$0.43

Thai Beverage Public Company (SGX:Y92) has an average rating of overweight and mean price target of SG$0.53, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

SGX:Y92
Research

Research Alert: Toll Brothers Beats Q2 Estimates But Guides Q3 Below Expectations

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Toll Brothers' Q2 revenue of $2.51B (-7% Y/Y) beat guidance and consensus, delivering 2,491 homes (-14% units) at ~$1,009k ASP (+8% Y/Y). EPS of $2.72 beat $2.59 consensus, driven by stronger-than-guided adjusted gross margin of 26.2% and favorable home mix. Strong operational execution demonstrated pricing power and cost control, though inventory impairments surged to $32.5M from $9.8M prior year. Q3 guidance fell short of consensus due to pull-forward of closings into Q2, but management raised full-year guidance across all metrics. Net orders grew 8% to $2.81B with backlog ASP rising to $1,171.8k, indicating higher-quality pipeline. However, sales pace per community declined Y/Y and spring selling season momentum of +23% sequential order growth fell short of typical +55% advance. We believe the Q3 shortfall reflects timing rather than fundamental weakness, though inventory impairments and moderated sales pace warrant monitoring in a challenging market environment.

$TOL
Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Under Armour Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $1 to $6, based on 17.1x our FY 28 (Mar.) EPS estimate and well below the company's three-year average forward P/E multiple of 31.4x. We lower our FY 27 EPS estimate by $0.30 to $0.15 and initiate our FY 28 EPS estimate at $0.35. UAA's revenue declined 0.8% to $1.17B, in line with consensus estimates (down 4.2% in constant currency), as a 7% decline in North America was partially offset by 10% international growth. The company posted adjusted diluted loss per share of $0.03 compared to a loss per share of $0.08 in the year prior and in line with consensus estimates. Gross margin compression of 470 bps to 42.0% represented the most significant headwind, primarily attributable to elevated tariff costs, along with pricing pressures, higher product costs, and unfavorable regional mix. This more than offset benefits from disciplined expense management, as SG&A declined 15% to $518M, reflecting lower marketing spend due to timing shifts and reduced compensation.

$UAA